The International Linked Clinical Trials programme (iLCT) is one of the largest drug repurposing initiatives in medical research. A recent review article provides an overview of the history, structure and progress of this successful programme.
On 20 April, Van Andel Institute are holding a virtual webinar which will feature presentations and a Q&A session with international Parkinson’s disease experts including Cure Parkinson’s Drs. Richard Wyse and Simon Stott.
Researchers have been investigating a waxy substance on our skin (called sebum) as a possible way of determining who does or does not have Parkinson’s.
MOVES-PD is a global phase 2 study to assess the efficacy and safety of the drug venglustat in Parkinson’s patients who have a GBA-1 gene mutation. Sanofi designed the venglustat clinical trial to assess changes in the course of the disease.
New research has found that there is convincing evidence that Type 2 diabetes is associated with a greater risk of Parkinson’s, but may in turn allow for better management of the disease.